WEBULL
WebtradeDownload

Is Nuvation Bio (NUVB) Undervalued Following Its Phase III Safusidenib Milestone?

Simply Wall St · 1d ago

Nuvation Bio (NUVB) has advanced safusidenib into a pivotal Phase III trial in high grade IDH1 mutant glioma, a clear milestone that can reshape how investors view its focused brain tumor franchise.

Despite the Phase III inflection point, Nuvation Bio’s share price has come under pressure, with the 30 day return down 19.28% and the year to date share price return down 42.89%, even as the 1 year total shareholder return of 33.15% and the very large 3 year total shareholder return of 308.33% reflect how strongly the story has already been repriced over a longer horizon.

Scan beyond Nuvation Bio and compare this late stage oncology story with 20 high quality undiscovered gems that investors are starting to notice in high potential corners of the market.

Nuvation Bio has just hit a major clinical milestone while the share price has slid back to US$4.90. Is this the moment to lean in, or does waiting for an even cheaper entry make more sense as valuation comes into focus next?

Most Popular Narrative: 63% Undervalued

Against Nuvation Bio’s last close at $4.90, the most followed valuation storyline points to a fair value of $13.11, which frames a wide gap that investors need to explain through the glioma and lung cancer opportunity.

Advancement of safusidenib into a pivotal Phase III high grade IDH1 mutant glioma maintenance study, targeting a population underserved by existing therapies, could position the company to tap into a durable brain tumor market and add a second meaningful revenue pillar that has the potential to scale earnings beyond IBTROZI.

See why 9 investors see Nuvation Bio as 63% undervalued.

Result: Fair Value of $13.11 (UNDERVALUED)

Still, the Nuvation Bio story hinges on a long safusidenib timeline and heavy reliance on IBTROZI, so delays or competitive shifts could quickly challenge this undervaluation case.

Find out about the key risks to this Nuvation Bio narrative.

Next Steps

If this all feels optimistic, that is exactly why it pays to move quickly, pull up the underlying numbers, and challenge the crowd’s view. To see what those optimistic investors are focusing on, start by reviewing the 2 key rewards.

Looking for more Nuvation Bio sized opportunities?

Do not stop with Nuvation Bio. Use the same disciplined lens on other ideas so you are not relying on a single clinical outcome or ticker.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.